You will collaborate closely with biologists, chemists, computer scientists and microscope engineers to create and leverage new assays and screening . Lead investigational products AT-001 and AT-007, part of our larger Aldose Reductase Inhibitor (ARI) franchise, are currently in clinical trials. This is an opportunity to significantly impact Eikon's drug discovery pipeline and work in a fast-paced and highly . Blue Therapeutics today u nveiled their disruptive IND stage receptor-interactomics TM platform and pipeline. . Wren Therapeutics, founded in 2016, is a spin-off company from the University of Cambridge (UK) and Lund University (Sweden). 3929 POINT EDEN WAY HAYWARD CA 94545; United States; HAYWARD, Calif.-Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the execution of a long-term lease with Alexandria Real Estate Equities, Inc. for its new corporate headquarters. Company Overview. Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the intersection of chemistry, engineering, computation, and biology to discover . Email Formats. 10 free leads on us . . Their latest funding was raised on Jan 6, 2022 from a Series B round. It offers platforms that permit precise characterization of protein interactions in living cells with spatial and temporal resolution. Pipeline. Eikon Therapeutics is a drug discovery and development company that leverages super-resolution microscopy as well as the latest advances in biology, chemistry, engineering, and automation toward the goal of discovering and inventing innovative therapies that will improve and extend life. . Since its founding two years ago, Eikon Therapeutics has raised more than $668 million to advance its mission of . Companies like Eikon Therapeutics. HAYWARD, Calif. - January 6, 2022 - Eikon Therapeutics, Inc., a pioneer in the application of live-cell super-resolution microscopy to drug discovery, today announced that it has closed a $517.8 million Series B financing. Uncover why Eikon Therapeutics is the best company for you. HAYWARD, Calif. - June 16, 2022 - Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the execution of a long-term lease with Alexandria Real Estate Equities, Inc. for its new corporate headquarters. . You will collaborate closely with biologists, chemists, computer scientists and microscope engineers to create and leverage new assay and screening . HAYWARD, Calif.-- ( BUSINESS WIRE )--Eikon Therapeutics, Inc., a pioneer in live-cell super-resolution microscopy and engineering for drug discovery, today announced that it has closed a $148. HAYWARD, Calif., March 23, 2022--Dr. Roy D. Baynes has been appointed Executive Vice President and Chief Medical Officer of Eikon Therapeutics effective July 11, 2022. Similar companies and competitors in the areas of Biotech, Health, Life Sciences, drug discovery and more. Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the intersection of chemistry, engineering, computation, and biology to discover novel treatments for life-threatening diseases. . Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the intersection of chemistry, engineering, computation, and biology to discover novel treatments for life-threatening diseases. Eikon Therapeutics, co-founded by Betzig, is a biopharmaceutical company with plans to use super-resolution fluorescence microscopy, the data collected by these high-powered microscopes and a host . Washington is among the most experienced business leaders in the . Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the intersection of chemistry, engineering, computation, and biology to discover novel treatments for life-threatening diseases. Eikon Therapeutics is a biopharmaceutical company that provides a method of drug discovery based on tracking and measuring the movement of individual proteins in live cells. Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the intersection of chemistry, engineering, computation, and biology to discover novel treatments for life-threatening diseases. Peloton Therapeutics is advancing a first-in-class discovery and development pipeline in oncology . Eikon's new headquarters will consist of . HAYWARD, Calif. & NEW YORK, July 21, 2022 -(BUSINESS WIRE)-Eikon Therapeutics Inc., a biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the execution of a lease with Alexandria Real Estate Equities, Inc. for its new East Coast base of operations located in the Alexandria Center for Life . Prior to Novartis, Ben held positions of increasing responsibility with Amgen in . THE NOBEL PRIZE IN CHEMISTRY 2014 POPULAR SCIENCE BACKGROUND How the optical microscope became a nanoscope Eric Betzig, Stefan W. Hell and William E. Moerner are awarded thNobePrize iChemistry 2014 for having bypassed a presumed scientic limitation stipulating that an optical microscope can never HAYWARD, Calif. & NEW YORK--(BUSINESS WIRE)-- Eikon Therapeutics Inc., a biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the execution of a lease with Alexandria Real Estate Equities, Inc. for its new East Coast base of operations located in the Alexandria Center for Life Science in New . 1d. . Dr. Halpryn has extensive experience in designing and leading biologics and small molecule drug development programs and companies across a broad range of therapeutic areas. Wren is using its unique approach to develop a broad pipeline of small . Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the intersection of chemistry, engineering, computation, and biology to discover novel treatments for life-threatening diseases. The company develops tools for . Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the intersection of chemistry, engineering, computation, and biology to discover novel treatments for life-threatening diseases. Prior to Eikonoklastes, Bruce co-founded Myonexus Therapeutics (acquired by Sarepta in 2018), and served as Chief Operating Officer and as a member of its Board of Directors. Company Number C4313120 Status Active Incorporation Date 9 September 2019 (about 3 years ago) Company Type FOREIGN STOCK Jurisdiction California (US) Branch Branch of EIKON THERAPEUTICS, INC. (Delaware (US)) Registered Address. Fierce Next Gen: Eikon drops hints at early pipeline, plans for $660M-plus reservoir. The offering reportedly sets an initial valuation for the company of around $1.4 billion. Eikon Therapeutics has raised a total of $666M in funding over 3 rounds. Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the intersection of chemistry, engineering, computation, and biology to discover novel treatments for life-threatening diseases. . HAYWARD, Calif., March 31, 2022 -- ( BUSINESS WIRE )--Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the. Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the intersection of chemistry, engineering, computation, and biology to discover novel treatments for life-threatening diseases. Founded in 2011, the company previously raised just over $500 million in known funding, per Crunchbase data. Applied Therapeutics is developing a pipeline of novel products that target molecules and pathways with proven roles in disease biology. Company Description. Flush with cash, the 170-person team is "growing rapidly across all functions," said Dan Anderson, Ph.D., chief scientific officer, At Eidos Therapeutics, we believe that retaining TTR will preserve healthy biology, physiologic homeostasis, and may yield optimal long-term outcomes ATTR-CMa path to disease Due to a genetic variant or unknown factors associated with aging, TTR tetramers can become unstable, leading to dissociation into component monomers that are prone to . Chat with local people in Nong Kham and Chon Buri right now! Company Description Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the intersection of chemistry, engineering, computation, and biology to discover novel treatments for life-threatening diseases. . Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the intersection of chemistry, engineering, computation, and biology to discover novel treatments for life-threatening diseases. . Millbrae, Calif.-based biotech firm Eikon Therapeutics is setting up a base of operations on the East Coast in the Alexandria Center for Life Science.. Eikon leased 25,000 square feet in the mixed-use facility at 430 East 29th Street, owned by Alexandria Real Estate Equities, to use for clinical development in New York City and to tap into the local talent pool, according to the company. Eikon Therapeutics. Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery. As a Scientist in the Biochemistry team at Eikon, you will support advancement of our broad drug discovery pipeline, playing a key role in developing and implementing a wide variety of novel assays. Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the intersection of chemistry, engineering, computation, and biology to discover novel treatments for life-threatening diseases. Team Members. Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the intersection of chemistry, engineering, computation, and biology to discover novel treatments for . Molecular Imaging. Eikon Therapeutics is funded by 18 investors. Eikon's discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the . Eikon's pipeline is designed to achieve effective therapeutics for unmet . both to supplement Eikon's homegrown pipeline and to ensure that our growing research and clinical development teams . Contact Information Website www.eikontx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Other Industries Biotechnology Primary Office 3929 Point Eden Way Hayward, CA 94545 United States +1 (341) 000-0000 Eikon Therapeutics Timeline 2020 2021 2022 . Hotels in Nong Kham. https://lnkd.in/gvVkMZhG Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening . Ben Thorner serves as General Counsel & Chief Business Officer of Eikon Therapeutics, and as such oversees all legal matters and deal-making for the Company. Identify and deliver service improvements in the HTS pipeline by employing process improvement methodologies and the . Search for and book hotels in Nong Kham with ViaMichelin: boutique, design and luxury hotels from 1 to 5 stars. . Our proprietary platform leverages Nobel Prize-winning super-resolution microscopy, advanced engineering, and automation with the . Prior knowledge of the drug discovery/development pipeline is a plus Eikon is proud to be an equal opportunity employer . Lead the building of forward-looking predictive financial models and tools supporting our pipeline portfolio. Eikon's discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the . Advances in super-resolution fluorescence microscopy has now made it possible to follow the dynamics of individual proteins in living cells. Launched: May 2021 491 followers. Develop documentation, adhere to . Compare pay for popular roles and read about the team's work-life balance. Tons of money raised Cons Located in East Bay (not many fun activities around) See All 4 Reviews Our AMP platform, originally developed at MIT, has broad potential across cancers, infectious diseases and other disease indications to advance a number of development initiatives through internal activities, in-licensing arrangements or development collaborations and partnerships. Company Description. For centuries, in order to observe cells in the body on a . Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the intersection of chemistry, engineering, computation, and biology to discover novel treatments for life-threatening diseases. Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the intersection of chemistry, engineering, computation, and biology to discover novel treatments for life-threatening diseases. Research salary, company info, career paths, and top skills for Sr. Optical Design Engineer Find contact information for Eikon Therapeutics. EIKON THERAPEUTICS, INC. branch. Use our Chrome Extension & instantly connect with prospects Download Free . . Business Area (s): Drug Discovery. Faqs. Ground-breaking core technology (Nobel prize Chemistry 2014) in drug discovery 2. Train and manage the performance of staff while supporting our screening pipeline. By Max Bayer Jun 30, 2022 02:20pm. New to the SBGrid collection in August: MemBrain, a pipeline for automated detection of membrane-bound proteins in cryo-electron tomograms utilizing the . medicinal chemistry and pharmacology expertise. Horizons Ventures and Foresite Capital are the most recent investors. Eikon Therapeutics Jun 2021 - Present1 year 4 months San Francisco Bay Area Vice President, Corporate & Business Development Veracyte, Inc. Apr 2019 - Jun 20212 years 3 months South San Francisco. Track, analyze experimental metrics, and foster awareness of the status of experiments in the pipeline for all key . Single Cell Analysis. Congratulations to this group! HAYWARD, Calif.-- (BUSINESS WIRE)-- #BayArea--With approximately 285,000 square feet, Eikon Therapeutics will be the anchor tenant of the campus, with space to accommodate up to 750 employees. . . Eikon Therapeutics Merck Ken Frazier Nobel Prize. Share. HAYWARD, Calif.--(BUSINESS WIRE)--Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Robin L. Washington as an independent director effective May 12, 2022.Ms. Eikon Therapeutics is using super-resolution microscopy for drug development. Additional clinical trials in other indications are . The lead asset BLUE-181 is approaching IND and has provided the robust proof of . . Jan 14, 2022 - Scientist in Hayward, CA Recommends Positive Outlook Pros 1. Technologies. Learn about their Business Services, Research & Development market share, competitors, and Eikon Therapeutics's email format. Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the intersection of chemistry, engineering, computation, and biology to discover novel treatments for life-threatening diseases. World-class leadership team (former Merck Research president Roger Perlmutter as CEO) 3. Eikon's discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the . . . Blue Therapeutics featured in GEN December 3 2021 "Targeted Therapies to Reduce Side Effects in Modern Drug Development" December 3 2021 Waltham, MA. Eikon Therapeutics, Inc., a pioneer in live-cell super-resolution microscopy and engineering for drug discovery, today announced that it has closed a $148 million Series A financing led by The Column Group with participation from Foresite Capital, Innovation Endeavors and Lux Capital. These categories were: finance, collaborations, pipeline, growth potential and innovation. Hayward, California, United States 101-250 Series B Private www.eikontx.com 2,056 Highlights Total Funding Amount $666M Contacts 21 Employee Profiles 4 Investors 18 Similar Companies 7 Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the intersection of chemistry, engineering, computation, and biology to discover novel treatments for . HAYWARD, Calif., May 16, 2022--Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important . Eikon Therapeutics is a new biopharmaceutical company employing the revolutionary technology of single molecule imaging at the intersection of chemistry, engineering and biology to discover novel treatments for life-threatening diseases. Chief Information Officer Eikon Therapeutics Nov 2021 - Present10 months Chief Information Officer PACT Pharma Mar 2020 - Oct 20211 year 8 months South San Francisco, California, United States -. he led a team of deal negotiators responsible for pre-PoC deals for Novartis' therapeutics pipeline. After raising more than $660 million in less than a year, Eikon Therapeutics' future plans are coming into clearer view, with an oncology pipeline underway as the star-studded biotech looks to capitalize onand expandNobel Prize-winning tech. SBGrid Consortium. Website: Eikon Therapeutics. Eikon Therapeutics Announces Long-Term Lease with Alexandria Real Estate Equities, Inc. for New Corporate Headquarters in the San Francisco Bay Area. Eikon Therapeutics I n 2014, the Nobel Prize in Chemistry was awarded to three men whose work helped change the way microscopes work. Funding. As a Principal Scientist in the Biology team at Eikon, you will drive the advancement of our broad drug discovery pipeline, leading the biology efforts for some of our drug discovery programs. Eikon's discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014 . Description: Eikon is pioneering a new method of drug discovery based on tracking and measuring the movement of individual proteins in living cells. Substantial pipeline and partnering. Create optical models of functional modules of our next generation SPT microscope stations empowering Eikon's drug . Eikon Therapeutics is a drug discovery and development company. View the job description, responsibilities and qualifications for this position. Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the intersection of chemistry, engineering, computation, and biology to discover novel treatments for . As we continue to build on our vision here at Eikon Therapeutics, a new position has opened in the Clinical group for an Executive Director, Early Clinical Scientist.If this is you or someone in your network, click the link below, Roy Baynes and I are looking forward to speaking with you! The Santa Monica, California-based company priced shares for its IPO at $16 each, toward the higher end of the projected range of $14 to $17. Eikon's discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells, thereby unlocking otherwise intractable classes of proteins as drug targets. assets and opportunities. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Manage the building of forward-looking predictive financial models and tools supporting our pipeline portfolio. Find out what works well at Eikon Therapeutics from the people who know best. Position Eikon Therapeutics, a new biotech startup that uses advanced techniques for visualizing proteins and combines that capability with computational approaches to drug screening , has emerged from .